急性冠状动脉综合征患者早期辛伐他汀干预对血脂和高敏C反应蛋白的影响_医学论文.docVIP

急性冠状动脉综合征患者早期辛伐他汀干预对血脂和高敏C反应蛋白的影响_医学论文 急性冠状动脉综合征患者早期辛伐他汀干预对血脂和高敏C反应蛋白的影响_医学论文 【关键词】 急性冠状动脉综合征 　　【摘要】 目的 观察急性冠状动脉综合征（ACS）患者早期辛伐他汀治疗对血清高敏C反应蛋白（hsCRP）和血脂水平的影响，探讨他汀类药物在ACS早期干预中的作用。方法 选择住院的ACS患者80例，采用随机、单盲、对照方法将ACS患者分为对照组（n=38,每日口服安慰剂）和辛伐他汀治疗组(n=42, 辛伐他汀20 mg/d，发病48 h内开始服用)，两组其他治疗相同；观察4周，于治疗前后分别检测患者血清hs-CRP及血脂的浓度。hsCRP浓度采用酶联免疫吸附法测定,血脂采用酶法。结果 治疗4周后，辛伐他汀组与对照组相比，患者血清hsCRP和总胆固醇（TC）、甘油三酯（TG）及低密度脂蛋白胆固醇（LDLC）浓度显著降低（P均lt001），而对照组治疗前后差异无显著性（均为Pgt005）。结论 ACS患者早期辛伐他汀治疗可明显改善血脂，降低hsCRP水平。辛伐他汀具有减少炎症反应和稳定斑块的作用。 　　【关键词】 急性冠状动脉综合征；C反应蛋白；血脂；辛伐他汀 　　【Abstract】 Objective to observe the effect of simvastatin on serum lipids and high sensitive Creactive protein(hsCRP) at the early stage in patients with acute coronary syndrome (ACS).Methods 80 hospitalized patients with ACS were selected and were randomly divided into control group(with placebo for 4 weeks, n=38) and simvastatin group(with simvastatin 20mg per day,n=42). Simvastatin and placebo were used within 48 hours from onset,and there were no other different therapeutic methods between two groups. The concentrations of serum lipids and hsCRP were detected before and after 4 weeks treatment by ELISA and enzymatic cholesterol assay.Results In simvastatin group, levels of serum total cholesterol(TC),triglycerides(TG), lower density lipid cholesterol(LDLC) and hsCRP decreased significantly compared with those before treatment (001) ,but there was no significant change in control group(Pgt005), Conclusion Simvastatin can lower levels of serum lipids and hsCRP in patients with acute coronary syndrome at the early stage, therefore simvastatin has antiinflammatory therapeutic effect and may stabilize atherosclerotic plaques. 　　【Key Words】 acute coronary syndrome, Creactive protein, serum lipids,simvastatin 　　急性冠状动脉综合征（acute coronary syndrome,ACS）是心血管内科常见病，包括急性心肌梗死、不稳定型心绞痛和心脏缺血性猝死。越来越多的证据表明炎症参与了动脉粥样硬化斑块的形成和发展，尤其是ACS的发生发展。高敏C反应蛋白（high sensitive Creactive protein,hsCRP）是目前最可靠的动脉粥样硬化炎症标志物，与斑块的进展密切相关，现已被视为心血管疾病重要的独立危险因子，并被用于判定其预后的标志［１］。他汀类药物具有调节